Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07614984 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 66 → 70 locations
  2. Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC Trial sites expanded: 54 → 66 locations · Eligibility criteria expanded, about 11 words · Secondary endpoints: details revised at 2 of 8 entries Show 3 more changesShow less
    • Trial sites expanded: 54 → 66 locations
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 2 of 8 entries
  3. Trial sites expanded: 32 → 54 locationsv9
  4. Study sites: 31 to 32v8
  5. Trial sites expanded: 23 → 31 locationsv7
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 22 to 23v6
  2. Study sites: 20 to 22v5
  1. Trial sites expanded: 12 → 20 locationsv4
  2. Trial sites expanded: 8 → 12 locationsv3
  3. Recruitment opened Trial sites expanded: 0 → 8 locations · Start date changed from estimate of Jul 7, 2026 to Jun 30, 2026v2 Show 2 more changesShow less
    • Trial sites expanded: 0 → 8 locations
    • Start date changed from estimate of Jul 7, 2026 to Jun 30, 2026
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck (MSD)
407 trials monitored
See 29 trials at risk
Researchers designed a trial medicine called MK-7262 to lower levels of Lp(a) in the blood. Researchers want to learn about giving MK-7262 with another trial medicine called enlicitide (also known as MK-0616 or enlicitide decanoate). Enlicitide is in a group of medicines that lower the amount of low-density lipoprotein cholesterol (LDL-C). The goals of this trial are to evaluate: * if MK-7262 and enlicitide taken together work better than placebo at lowering Lp(a) and LDL-C levels in the blood * if MK-7262 alone works better than placebo at lowering Lp(a) levels in the blood * the safety and tolerability of taking MK-7262 and enlicitide alone and together
Trial Details
NCT Number NCT07614984
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Lipoprotein(a)
Enrollment 750 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov